Abstract:Purpose: Approximately 20 % of tumors have the opportunity to be resected in patients with hepatocellar carcinoma (HCC) and their prognoses were acceptable. For the unrespectable HCC, however, the outcomes were rather poor because the specialty of the tumor blood supply and the tumor was insensitive to the chemotherapy drug. The objective of this study was to find sensitive drugs for individual patients and determine the safety and antitumor activity of hepatic intra-arterial and portal vein infusion chemotherapy. Methods: A total of 120 patients with the mean patient age of 56 years and with unresectable HCC were randomly divided into experimental group and control group. The experiment group was infused through an intra-arterial and portal vein catheter 3 different drugs were chosen by the results of drug sensitive test, whereas the control group was treated for TACE. The changes in tumor-size and AFP, two-step operation rate, survival rate, and complications were observed in these patients. Results: The tumor size reduced in 28(47.6 %) cases, stabilized in 14(23.3 %) cases, and progressed in 18(30 %) cases in experimental group as measured by CT or MRI after six chemotherapy cycles, whereas the corresponding data was 17(28.5 %) cases, 7(11.5 %) cases and 36(60 %) cases in the control group (P < 0.05). The AFP was declined in 51 cases in experimental group and in 30 cases in control group (P < 0.05). In the experimental group, the median follow-up time was 21 months; the overall survival rates (OS) of 6 months, 12 months, and 18 months were 86 %, 72 %, and 65 %, respectively. In the control group, the median follow-up time was 16 months; the OS rates of 6 months and 12 months were 58 % and 40 %, respectively. Six patients in the experimental group and 3 patients in the control group had two-step operation. There was no severe incidence of complications in both groups. In the experimental group, 2 (3 %) patients had wound infection, 8 cases had the chemotherapy relative diarrhea, and 18 (30 %) cases had grade Ⅰ or Ⅱ bone marrow suppression. In the control group, the chemotherapy relative diarrhea were 15 (25 %) cases and grade Ⅰ or Ⅱ bone marrow suppression were 33 (55 %) cases. Conclusion: The artery and portal vein pump transfusion chemotherapy guided by drug sensitive test was efficient for HCC treatment. The patients can get longer OS and lower complication incidence.--------------------------------------------------------Cite this article as: Wu D, Wei S, Luo C, Wu X, Feng Y, Zhang F, Nie L, Xia X. Clinical study on the sensitivity test guided hepato-arterial/portal -vein chemotherapy in patients with unresectable hepatocellar carci-noma. Int J Cancer Ther Oncol 2014; 2(2):02029. DOI: 10.14319/ijcto.0202.9

Preliminary Survival Observation on Purcutaneous Portal Vein Chronomodulated Chemotherapy on Treatment of Liver Cancer.

Combined Three Intervened Treatment of TACE,PEI And PVC in Advanced Liver Cancer

Prolong Overall Survival Rate for Patients with Liver Cancer Receiving Double Interventional Therapy

[Clinical Effect of Terminal Branches Portal Vein Embolization Combined with Transcatheter Arterial Chemoembolization on Liver Neoplasms].

Systematic sequential therapy for <i>ex vivo</i> liver resection and autotransplantation: A case report and review of literature

Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Chemotherapeutic Perfusion of Portal Vein after Tumor Thrombectomy and Hepatectomy Benefits Patients with Advanced Hepatocellular Carcinoma: A Propensity Score‐matched Survival Analysis

The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis

Clinical Study on the Sensitivity Test Guided Hepato-Arterial/portal-vein Chemotherapy in Patients with Unresectable Hepatocellar Carcinoma

Transcatheter arterial chemoembolization combined with endovascular 125I seed strip implantation for primary hepatocellular carcinoma associated with portal vein tumor thrombus：analysis of curative effect

Endovascular Brachytherapy Combined with Portal Vein Stenting and Transarterial Chemoembolization Improves Overall Survival of Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus.

Hepatocellular Carcinoma Invading the Main Portal Vein: Treatment with Transcatheter Arterial Chemoembolization and Portal Vein Stenting

Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens

Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

A Clinical Observation of Intra—arterial Chenotherapy Combined with Thermotherapy for Prinary Liver Cancer after TACE

PD-1 combined with lenvatinib and TACE for the transformational treatment of hepatocellular carcinoma combined with portal vein tumor thrombus: a case report and literature review

Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: a Meta-Analysis.

Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis

Transarterial Chemoembolization Versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus：a Multicenter Study.

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices